www.cellmade.com looks set to become a primary resource for drug discovery and preclinical researchers working in inflammatory diseases.
Proprietary human primary co-culture models, primary human cells and stem cells, coupled with cytokine secretion assays and lipid bioanalysis, enables the CellMade team to identify and characterise the best biomarkers of early inflammatory response for drug discovery projects. These are critical tools to help companies to evaluate the safety and efficacy of their new drugs. In addition, the company uses its unique technology to develop companion tests for personalized medicine.
Ronald Bronsaer, Chief Executive Officer, CellMade said: “There is a growing need for effective companion tests for anti-inflammatory drugs, as patients and FDA concerns grow regarding the costs and unwanted side effects of the TNF-alpha antagonists. CellMade technology is being used to identify people who would benefit from such treatments, and to giving early warning signs of toxicity before clinical symptoms develop. The new website is a perfect vehicle to showcase our expertise and specialist knowledge in this area.”